A 2-week study in healthy postmenopausal volunteers treated with 20 μ g per day ethinylestradiol showed that pre-treatment with 250 mg fulvestrant resulted in significantly reduced stimulation of the postmenopausal endometrium, compared to pre-treatment with placebo, as judged by ultrasound measurement of endometrium thickness